



FFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elisabetta Bianchi et al.		Confirmation No:	TBA	
Serial No.:	10/583,491	Case No.:	ITR0054P	Art Unit:	TBA
Filed:	June 15, 2006		Examiner:	TBA	
For:	A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGTE WITH A HIGH IMMUNOGENICITY				

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Response to Notification of Defective Response

Sir:

In response to the Notification of Defective Response mailed November 19, 2008, submitted herewith is a Sequence Listing (in computer readable and written form) and a Statement In Accordance With 37 CFR §§ 1.821-1.825.

No fee is believed to be due. However, the Commissioner is hereby authorized to charge any additional fees which may be required to deposit account 13-2755.

Respectfully submitted,

Dated: 25 November 2008

By:

Melissa B. Wenk

Reg. No. 53,759

Attorney for Applicants

Correspondence Address:

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-2756 Telephone  
(732) 594-7790 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By Date 11/25/2008  
MERCK & CO., INC.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elisabetta Bianchi et al.		Confirmation No:	TBA	
Serial No.:	10/583,491	Case No.:	ITR0054P	Art Unit:	TBA
Filed:	June 15, 2006		Examiner:	TBA	
For:	A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGTE WITH A HIGH IMMUNOGENICITY				

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT IN ACCORDANCE WITH 37 CFR §§ 1.821-1.825


Sir:

Enclosed is a Sequence Listing in computer readable and written form. I hereby state that the information recorded in computer readable form of the Sequence Listing is identical to the written form of the Sequence Listing.

Respectfully submitted,

Dated: 25 November 2008

By:

  
Melissa B. Wenk  
Reg. No. 53,759  
Attorney for Applicants

Correspondence Address:


Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-2756 Telephone  
(732) 594-7790 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By:

Date

 11/25/2008



## SEQUENCE LISTING

<110> Elisabetta Bianchi  
 Antonello Pessi  
 Marco Finotto  
 Paolo Ingallinella

<120> A METHOD TO MAKE A PEPTIDE-CARRIER  
 CONJUGATE WITH A HIGH IMMUNOGENICITY

<130> ITR0054P

<140> 10/583,491

<141> 2006-06-15

<150> 60/530,867

<151> 2003-12-18

<150> PCT/EP2004/014160

<151> 2004-12-14

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 1

Cys	Gly	Pro	Glu	Lys	Gln	Thr	Arg	Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly
1				5					10					15	
Phe	Ile	Glu	Asn	Gly	Asn	His									
			20												

<210> 2

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 2

Ala	Cys	Gly	Pro	Glu	Lys	Gln	Thr	Arg	Gly	Leu	Phe	Gly	Ala	Ile	Ala
1				5					10					15	
Gly	Phe	Ile	Glu	Asn	Gly	Glu	His								
			20												

<210> 3

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 3

Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile  
 1 5 10 15  
 Glu Asn Gly Cys Asn His  
 20

<210> 4

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 4

Ser Glu Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly  
 1 5 10 15  
 Phe Ile Glu Asn Gly Cys His  
 20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 5

Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln  
 1 5 10 15  
 Leu Cys Asn His  
 20

<210> 6

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 6

Ser Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg  
 1 5 10 15  
 Gln Leu Cys Asn His  
 20

<210> 7

<211> 29

<212> PRT

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Chemically Synthesized

&lt;400&gt; 7

Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly
1				5					10					15	
Met	Ile	Asp	Gly	Gly	Cys	Gly	Lys	Lys	Lys	Lys	Asn	His			
			20					25							

&lt;210&gt; 8

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Chemically Synthesized

&lt;400&gt; 8

Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Trp	Glu	Gly
1				5					10					15	
Met	Val	Asp	Gly	Cys	Glu	His									
			20												

&lt;210&gt; 9

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Chemically Synthesized

&lt;400&gt; 9

Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Cys	Glu	His
1				5					10					15	

&lt;210&gt; 10

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Chemically Synthesized

&lt;400&gt; 10

Ala	Gly	Leu	Phe	Gly	Ala	Ile	Ala	Gly	Phe	Ile	Glu	Asn	Gly	Cys	Glu
1				5					10					15	
His															

&lt;210&gt; 11

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Chemically Synthesized

ITR0054P

<400> 11  
Ser Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Cys Glu  
1 5 10 15  
His